Activist Starboard drops out of Celgene fight as proxy firms back Bristol-Myers bid

Activist investor Starboard Value has ended its fight against Bristol-Myers Squibb's buyout of peer biotechnology company Celgene following recommendations in favor of the deal from Glass Lewis and Institutional Shareholder Services.

This is a developing story. Check back here for more updates.

Subscribe to CNBC on YouTube.

Let's block ads! (Why?)

from Top News & Analysis https://ift.tt/2TI6JhN